ERBB2 and neoplasm: After adjusting for these characteristics, the DFS and OS rates were significantly better for ER+/HER2+ patients treated with trastuzumab than those with ER+/HER2- tumor, indicating HER2-positivity itself may not be an adverse factor for ER+ patients if they were treated with trastuzumab, which may guide further clinical treatment decision making.